Laboratory research material only. Not for human or animal consumption.
Home/Shop/PT-141 10mg
PT-141 10mg research peptide vial · Polaris Research

Hormonal & Libido · 10mg

PT-141 10mg

CAS 189691-06-3

$89
1
Free Express Delivery, No Minimum
Quality Certificate Included
Card, PayPal or PayID
Sealed Under Argon
Reserved for 24h Once Ordered

PT-141, formally bremelanotide and also written PT141 or PT 141, is a melanocortin-receptor agonist studied for centrally mediated signalling and libido-pathway research. Structurally it is a variant related to the melanocortin family, and it is the best-known compound in the libido research corner of the catalogue, studied for how it engages central melanocortin pathways rather than the vascular pathways older approaches targeted. The 10mg vial is the standard reference format.In preclinical models, bremelanotide is investigated for its activity at melanocortin receptors and the central signalling associated with them. It sits in a specialist niche of the range: the research interest is in precise receptor engagement rather than broad systemic pathways, which is why it is studied as a focused reference compound rather than a general-purpose one.PT-141 shares the melanocortin lineage with Melanotan 2, and researchers comparing melanocortin-pathway compounds often study the two side by side, they engage overlapping receptors but are investigated for different pathway emphases. The single-compound 10mg vial here is the standard reference format for bremelanotide on its own.Every 10mg vial ships lyophilised with an independently verified batch certificate at a guaranteed floor of ≥98% purity, verifiable on the batch verification page using the batch number on the label. Reconstitute with bacteriostatic water: add it slowly down the inside wall of the vial, swirl gently, and never shake. Store the unopened vial at 2 to 8°C; refrigerate the reconstituted solution and avoid repeated freeze-thaw cycles. CAS reference 189691-06-3.Buying PT-141 (bremelanotide) in Australia is domestic and direct: free Australia Post Express shipping Australia-wide with no minimum spend, dispatch from within Australia, and tracking on every parcel. Pay by card, PayPal, or PayID; each vial is sealed under argon with a 24-hour payment reservation on your stock. Supplied strictly as a research material for lawful laboratory and in-vitro use, not for human or veterinary consumption.

Formal Name
Bremelanotide
CAS Number
189691-06-3
Purity
99.4% · batch-tested
Description
Bremelanotide/PT-141 is a melanocortin receptor agonist studied for centrally mediated sexual-arousal signalling.
Research Focus
Melanocortin, libido, arousal and sexual-function pathway research.
Suggested Use
Reference plan: 1.75 mg aliquots for as-needed research exposure. Do not exceed one exposure in 24 hours or eight per month in label-based comparisons.
Doses per Vial
5 x 1.75 mg reference aliquots plus residual.
Concentration
1.75 mg per reference aliquot from a 10 mg vial.
Notes
Approved bremelanotide labelling is specific and includes cardiovascular and nausea warnings; keep copy conservative.

Prepared with care, sealed under argon, and stored at 2–8°C until dispatch. Reconstitute with Bacteriostatic Water before use. Full preparation and storage guidance included with your order.

Independent Research
Evidence Overview on reptides.co

Independent third-party research on reptides.co — not affiliated with Polaris Research. Research reference only, not medical advice.

Pairs Well With

Complete your order

Related Reading

From the library

Also Searched As·PT-141 is also searched as Bremelanotide, PT141, PT 141, Bremelanotide acetate, Melanotan II variant.

Research File

What has been published on PT-141

Steady

PT-141 appears in 135 indexed publications going back to 1995, including 11 in the past twelve months. 10 registered trials appear on ClinicalTrials.gov.

135
Indexed publications
11
Past 12 months
10
Registered trials
6,200
Monthly readers, down 15%
20152026

Publications per year. The final bar is the current year, still in progress.

Indexed publications per year
20152
20162
20177
20184
20198
20207
20219
202213
20236
20245
202511
202610
Read the full PT-141 research fileCounts from Europe PMC and ClinicalTrials.gov, refreshed weekly. Reported as a record of what exists, not as evidence of any effect.